Drugs / Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03522545 | Apr 2022 → Dec 2026 expected | bipolar depression | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03522545 ↗ |
| Known as | MSCs | “Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow” NCT03522545 ↗ |